The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.
Serious Concerns Cloud Potential Benefit of Liquid Biopsy in Cancer ScreeningFebruary 3rd 2022
Maurie Markman, MD, explains the concerns surrounding liquid biopsies in cancer screening, and why regulatory agencies should be cautious and not approve any proposed molecularly based cancer diagnostic screening strategy until the tool is shown to effect cancer-specific survival compared with a control population not undergoing such testing.
Making Progress Against the Blood-Brain BarrierJanuary 31st 2022
Primary and metastatic brain tumors present a significant therapeutic challenge, in large part because they are protected by the blood-brain barrier, a highly restrictive interface between the bloodstream and the brain that prevents most drugs from accessing the brain parenchyma.
Lorlatinib Approved in Europe for ALK+ Advanced NSCLCJanuary 28th 2022
The European Commission has granted a marketing authorization for lorlatinib for use as a single agent in the treatment of adult patients with ALK-positive advanced non–small cell lung cancer who did not receive a prior ALK inhibitor.
Targeting CD166 Represents a New Avenue of Attack for Breast CancerJanuary 12th 2022
High expression of activated leukocyte cell adhesion molecule, also known as CD166, occurs in approximately 50% of patients with triple-negative breast cancer and up to 80% of patients with estrogen receptor– positive, HER2-negative breast cancer.
Aggarwal Shines a Light on Precision Medicine in Lung, Breast, Ovarian, and GI CancersJanuary 6th 2022
Molecular testing is an established and essential precursor to treatment for patients with non–small cell lung cancer based on the volume of actionable targets, such as EGFR and KRAS G12C mutations, as well as PD-L1 status.
New Players Join Quest for a Therapeutic Foothold Against TGFβJanuary 3rd 2022
Bintrafusp Alfa, a novel fusion protein designed to target the transforming growth factor beta pathway, racked up 3 clinical trial disappointments in less than a year, leaving the future of its development in question.
FDA Greenlights Companion Diagnostic for BRAF Inhibitors in MelanomaDecember 8th 2021
The FDA has approved FoundationOne CDx for use as a companion diagnostic for 2 groups of current a future regulatory-approved treatments in melanoma, including single-agent BRAF inhibitors targeting BRAF V600E mutations and BRAF/MEK combination regimens targeting BRAF V600E or V600K mutations.
Multigene Panel Testing Identifies Actionable Germline Mutations in Newly Diagnosed Endometrial CancerNovember 26th 2021
Investigators identified potentially actionable germline variants in 10% of unselected women with newly diagnosed endometrial cancer, supporting the use of upfront multigene panel testing for all in the population.
FDA Grants Partial Recognition to Memorial Sloan Kettering’s OncoKB Database
The Food and Drug Administration has granted recognition to a partial listing of the Oncology Knowledge Base, a comprehensive precision oncology knowledge databased developed by investigators and physicians at Memorial Sloan Kettering Cancer Center.
Genomically-Guided Radiation Dosing Model Shows Promise in Various Cancer Types
Radiation oncologists Jacob Scott, MD, DPhil, and Javier Torres-Roca, MD, discuss the benefits of using GARD in a pooled pan-cancer analysis and why there is a call to action to integrate GARD-based radiotherapy dosing in oncology.
Genomic Testing Cooperative Seeks to Increase Accessibility to Genomic Profiling Across CancersNovember 2nd 2021
Maher Albitar, MD, discusses the unmet needs with genomic testing that served as the impetus to start GTC, the process of becoming a partner with the organization, and the importance of genomic profiling for all patients with cancer.
RP-3500 Shows Promising Safety, Clinical Activity in Solid Tumors With Synthetic Lethal Genomic AlterationsOctober 27th 2021
The ATR inhibitor RP-3500 demonstrated a manageable safety profile and promising early antitumor efficacy in patients whose tumors harbor select genomic alterations when administered at doses of 100 mg or more.
FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLCOctober 22nd 2021
The FDA has approved the VENTANA PD-L1 assay to assist in identifying which adult patients with stage II to IIIA non–small cell lung cancer whose tumors have PD-L1 expression on 1% or more of tumor cells are eligible to receive adjuvant atezolizumab following surgery and platinum-based chemotherapy.
FDA Greenlights Companion Diagnostic for Adjuvant Abemaciclib Plus Endocrine Therapy in High-Risk Early Breast CancerOctober 14th 2021
The FDA has approved the Ki-67 IHC MIB-1 pharmDx test to assist in determining which patients with early breast cancer who are at high risk of disease recurrence might benefit from adjuvant treatment with abemaciclib plus endocrine therapy.
Addressing AYA Cancer Requires a Tailored Approach to PracticeOctober 8th 2021
Investigators have expanded the scientific understanding of cancer in the adolescent young adult patient population over the past decade. However, unmet needs remain in establishing treatment standards, addressing unique survivorship challenges, and providing a framework for patients to reference as they navigate their cancer journey.
Key Advances Showcase the Potential of Precision Medicine in NSCLCOctober 5th 2021
The sustainability of next-generation sequencing will be dependent on the implementation of thorough informatics and infrastructure that can support the integration of genomic results into electronic medical records.
Goy Taps Into the True Potential of Precision Medicine in OncologySeptember 18th 2021
Current approaches to precision medicine in oncology have been fruitful, but require better integration and utilization of available resources to inform sustainable and effective drug development and clinical care, according to Andre Goy, MD.